Prostate cancer is a heterogeneous disease that remains dormant for long periods or acts aggressively with poor clinical outcomes. Identifying aggressive prostate tumor behavior using current glandular-focused histopathological criteria is challenging. Recent evidence has implicated the stroma in modulating prostate tumor behavior and in predicting post-surgical outcomes. However, the emergence of stromal signatures has been limited, due in part to the lack of adoption of imaging modalities for stromal-specific profiling. Herein, label-free multiphoton microscopy (MPM), with its ability to image tissue with stromal-specific contrast, is used to identify prostate stromal features associated with aggressive tumor behavior and clinical outcome. MPM was performed on unstained prostatectomy specimens from 59 patients and on biopsy specimens from 17 patients with known post-surgery recurrence status. MPM-identified collagen content, organization, and morphological tumor signatures were extracted for each patient and screened for association with recurrent disease. Compared to tumors from patients whose disease did not recur, tumors from patients with recurrent disease exhibited higher MPM-identified collagen amount and collagen fiber intensity signal and width. Our study shows an association between MPM-identified stromal collagen features of prostate tumors and post-surgical disease recurrence, suggesting their potential for prostate cancer risk assessment.
Journal of personalized medicine. 2021 Oct 22*** epublish ***
Ina P Pavlova, Sujit S Nair, Dara Lundon, Stanislaw Sobotka, Reza Roshandel, Patrick-Julien Treacy, Parita Ratnani, Rachel Brody, Jonathan I Epstein, Gustavo E Ayala, Natasha Kyprianou, Ashutosh K Tewari
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Department of Urology, Pasteur 2 University Hospital of Nice, 06000 Nice, France., Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Department of Pathology, Urology and Oncology, Johns Hopkins Hospital, Baltimore, MD 21287, USA., Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.